Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;4(5):572-8.
doi: 10.3978/j.issn.2223-4683.2015.08.03.

Intravesical liposome drug delivery and IC/BPS

Joseph J Janicki  1 , Michele A Gruber  1 , Michael B Chancellor  1
Affiliations
Review

Intravesical liposome drug delivery and IC/BPS

Joseph J Janicki et al. Transl Androl Urol. 2015 Oct.

Abstract

Intravesical therapy has previously shown to be effective in delaying or preventing recurrence of superficial bladder cancer. This local route of drug administration is now demonstrating promise in the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) with the benefit of minimal systemic side effects. Liposomes (LPs) are lipid vesicles composed of phospholipid bilayers surrounding an aqueous core. They can incorporate drug molecules, both hydrophobic and hydrophilic, and vastly improve cellular uptake of these drug molecules via endocytosis. Intravesical LPs have therapeutic effects on IC/BPS patients, mainly due to their ability to form a protective lipid film on the urothelial surface and repair the damaged urothelium. This review considers the current status of intravesical LPs and LP mediated drug delivery for the treatment of IC/BPS.

Keywords: Liposome (LP); bladder; interstitial cystitis (IC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors are Employees of Lipella Pharmaceuticals, Inc.

Figures

Figure 1
Figure 1
Mechanism of action with intravesical liposome instillation.
Figure 2
Figure 2
Intravesical liposome (LP-08) vs. standard of care oral pentosan polysulfate (PPS) (5).
Figure 3
Figure 3
Intravesical liposome (LP-08) reduces pain and urgency scores in symptomatic IC/BPS patients. Probability density functions for pain and urgency scores of patients at baseline, 8 and 12 weeks. The leftward shift of the curves following LP-08 treatment indicates reduced pain and urgency symptoms (20).
See this image and copyright information in PMC

References

    1. Weintraub MD, Li QQ, Agarwal PK. Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review). Mol Clin Oncol 2014;2:656-60. - PMC - PubMed
    1. Hsu CC, Chuang YC, Chancellor MB. Intravesical drug delivery for dysfunctional bladder. Int J Urol 2013;20:552-62. - PubMed
    1. Apodaca G. The uroepithelium: not just a passive barrier. Traffic 2004;5:117-28. - PubMed
    1. Cortesi R, Nastruzzi C. Liposomes, micelles and microemulsions as new delivery systems for cytotoxic alkaloids. Pharm Sci Technolo Today 1999;2:288-98. - PubMed
    1. Chuang YC, Lee WC, Lee WC, et al. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol 2009;182:1393-400. - PubMed